Ovarian cancer risk prediction
AssigneeArocell AB
InventorsKiran KUMAR JAGARLAMUDI, Staffan ERIKSSON, Josko OSREDKAR
Life of this patent
Estimating the term…
Abstract
Ovarian cancer risk is predicted for a female human subject by determining an amount of STK1 material in a serum or plasma sample from the female human subject using first and second monoclonal antibodies, or antigen-binding fragments thereof, specifically binding to a serum form of human TK1. An amount of CA 125 or HE4 is determined in the serum or plasma sample or another serum or plasma sample from the female human subject. Ovarian cancer risk is then predicted for the female human subject based on the amount of STK1 material and the amount of one, but not both, of CA 125 and HE4.
Claims25
1-21. (canceled)
A method for predicting ovarian cancer risk for a female human subject comprising:
- determining an amount of serum thymidine kinase 1 (STK1) material in a serum or plasma sample from the female human subject using a kit comprising a first monoclonal antibody, or a first antigen-binding fragment thereof, specifically binding to a serum form of human TK1 and a second monoclonal antibody, or a second antigen-binding fragment thereof, specifically binding to the serum form of human TK1;
- determining an amount of carcinoma antigen 125 (CA 125) or human epididymis protein 4 (HE4) in the serum or plasma sample or another serum or plasma sample from the female human subject;
- and
- predicting ovarian cancer risk for the female human subject based on the amount of STK1 material and the amount of one, but not both, of CA 125 and HE4.
The method according to method 22, wherein determining the amount of STK1 material in the serum or plasma sample comprises:
- contacting the serum or plasma sample with the first monoclonal antibody, or the first antigen-binding fragment thereof, and the second monoclonal antibody, or the second antigen-binding fragment thereof;
- and
- measuring an amount of the first monoclonal antibody, or the first antigen-binding fragment thereof, or the second monoclonal antibody, or the second antigen-binding fragment bound to the STK1 material.
A method for determining ovarian cancer biomarkers for a female human subject comprising:
- determining an amount of serum thymidine kinase 1 (STK1) material in a serum or plasma sample from the female human subject using a kit comprising a first monoclonal antibody, or a first antigen-binding fragment thereof, specifically binding to a serum form of human TK1 and a second monoclonal antibody, or a second antigen-binding fragment thereof, specifically binding to the serum form of human TK1;
- and
- determining an amount of carcinoma antigen 125 (CA 125) or human epididymis protein 4 (HE4), but not both of CA 125 and HE4, in the serum or plasma sample or another serum or plasma sample from the female human subject.
Dependencies are inferred from the claim text.